Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
$1.96
+3.2%		$2.41
$1.70
▼
$19.35
$18.96M1.2749,767 shs152,908 shs
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.46
-3.4%		$3.77
$3.10
▼
$7.20
$6.90M1.0937,322 shs19,918 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$3.24
-3.0%		$3.10
$2.77
▼
$12.15
$30.13M0.2646,817 shs55,694 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$1.52
-7.9%		$2.50
$1.44
▼
$16.25
$25.91M1.5348,997 shs43,967 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
0.00%-14.41%-26.36%-4.04%-85.25%
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
0.00%+0.56%-6.28%-8.21%-33.95%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
0.00%+2.14%+10.96%+4.37%-17.33%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
0.00%-5.66%-31.54%-60.05%-71.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
$1.96
+3.2%		$2.41
$1.70
▼
$19.35
$18.96M1.2749,767 shs152,908 shs
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.46
-3.4%		$3.77
$3.10
▼
$7.20
$6.90M1.0937,322 shs19,918 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$3.24
-3.0%		$3.10
$2.77
▼
$12.15
$30.13M0.2646,817 shs55,694 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$1.52
-7.9%		$2.50
$1.44
▼
$16.25
$25.91M1.5348,997 shs43,967 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
0.00%-14.41%-26.36%-4.04%-85.25%
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
0.00%+0.56%-6.28%-8.21%-33.95%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
0.00%+2.14%+10.96%+4.37%-17.33%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
0.00%-5.66%-31.54%-60.05%-71.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
2.20
Hold$20.33937.41% Upside
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.25
Hold$14.50319.08% Upside
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
2.67
Moderate Buy$11.00239.51% Upside
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
2.33
Hold$11.00623.68% Upside

Current Analyst Ratings Breakdown

Latest BOLT, EVAX, RADX, and ATOS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/9/2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/7/2026
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
Rodman & Renshaw logo
Rodman & Renshaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/AN/AN/AN/A$4.57 per shareN/A
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$7.70M0.87N/AN/A$13.81 per share0.25
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$7.53M3.88N/AN/A$2.04 per share1.59
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$1.88M12.69N/AN/A$1.28 per share1.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-$34.77M-$3.11N/AN/AN/AN/A-102.99%-85.78%11/11/2026 (Estimated)
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$33.38M-$16.44N/AN/AN/A-611.47%-126.23%-54.70%11/11/2026 (Estimated)
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-$7.71M-$1.21N/AN/AN/AN/A-61.43%-34.23%11/5/2026 (Estimated)
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
-$37.43MN/AN/AN/AN/AN/AN/AN/AN/A

Latest BOLT, EVAX, RADX, and ATOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$3.39-$4.57-$1.18-$4.57$0.50 million$0.01 million
8/7/2026Q2 2026
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-$1.02-$0.95+$0.07-$0.95N/AN/A
7/31/2026Q4 2026
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A-$0.81N/A-$0.8050N/A$0.49 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/AN/AN/AN/AN/A
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$0.3610.01%N/AN/A N/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
N/AN/AN/AN/AN/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/A
5.69
5.69
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
1.47
2.61
2.61
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
0.69
5.06
5.06
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
1.16
N/A

Institutional Ownership

CompanyInstitutional Ownership
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
12.74%
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
86.70%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
11.04%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A

Insider Ownership

CompanyInsider Ownership
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
9.80%
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
9.40%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
41.64%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
149.98 million9.00 millionOptionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
231.93 million1.75 millionNot Optionable
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
469.02 million5.27 millionNo Data
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
1415.70 millionN/AN/A

Recent News About These Companies

Radiopharm Theranostics (NASDAQ:RADX) Trading 1.1% Higher - Should You Buy?
September 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031865
Radiopharm Selected For Late-Breaking Presentation Of Positive RAD101 Phase 2b Data; Stock Up
September 14, 2026  |  rttnews.comhttps://www.rttnews.com/3690773/radiopharm-selected-for-late-breaking-presentation-of-positive-rad101-phase-2b-data-stock-up.aspx
Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro ...
September 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/radiopharm-theranostics-selected-breaking-oral-120000167.html
Radiopharm Theranostics Reports Positive Phase 1 Imaging Data For RAD 301 In Pancreatic Cancer
September 9, 2026  |  rttnews.comhttps://www.rttnews.com/3689598/radiopharm-theranostics-reports-positive-phase-1-imaging-data-for-rad-301-in-pancreatic-cancer.aspx
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358457/0/en/radiopharm-theranostics-announces-positive-data-from-the-phase-1-imaging-trial-of-rad301-in-patients-with-pancreatic-ductal-adenocarcinoma.html
Radiopharm Theranostics Ltd ADR (RADX)
September 1, 2026  |  investing.comhttps://www.investing.com/equities/radiopharm-theranostics-adr-financial-summary
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
August 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351185/0/en/radiopharm-theranostics-doses-first-patient-in-second-cohort-of-phase-1-2a-clinical-trial-of-betabart-rv-01-in-b7-h3-expressing-solid-tumors.html
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348199/0/en/radiopharm-theranostics-receives-positive-recommendation-from-data-safety-and-monitoring-committee-to-advance-to-cohort-4-in-177lu-rad202-phase-1-heat-clinical-trial.html
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/radiopharm-theranostics-meet-u-fda-113000466.html
RADX: RAD101 Topline & FY:26 Cash Flows
August 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/radx-rad101-topline-fy-26-151400375.html
Radiopharm Dips on Securities Pact
July 25, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23725/Radiopharm-Dips-on-Securities-Pact
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
July 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/24/3332785/0/en/radiopharm-theranostics-announces-concurrent-us-4-1-million-registered-direct-offering-and-up-to-additional-a-12-7-us-8-9-million-australian-placement-and-share-purchase-plan.html
Radiopharm Highlights Data Release
July 23, 2026  |  baystreet.cahttps://www.baystreet.ca/techinsider/5668/Radiopharm-Highlights-Data-Release
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331243/0/en/radiopharm-theranostics-achieves-confirmed-durable-partial-response-in-ongoing-phase-1-trial-of-rad204-in-patients-with-advanced-solid-tumors-post-immunotherapy.html
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331214/0/en/radiopharm-theranostics-announces-positive-phase-2b-trial-results-of-rad-101-for-diagnosis-of-brain-metastases.html
Radiopharm Theranostics Ltd ADR RADX
July 16, 2026  |  morningstar.comM
Radiopharm Theranostics Limited Sponsored ADR
May 14, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/RADX
RADX: Fiscal 3Q:26 Cash Flow Report
May 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/radx-fiscal-3q-26-cash-092400408.html
Radiopharm Theranostics Ltd. ADR
May 13, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/radx/financials
Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs
April 28, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/radiopharm-theranostics-adr-radx-inside-the-clinical-programs-1748993/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atossa Genetics stock logo

Atossa Genetics NASDAQ:ATOS

$1.96 +0.06 (+3.16%)
Closing price 04:00 PM Eastern
Extended Trading
$1.96 0.00 (-0.26%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Bolt Biotherapeutics stock logo

Bolt Biotherapeutics NASDAQ:BOLT

$3.46 -0.12 (-3.35%)
Closing price 03:55 PM Eastern
Extended Trading
$3.58 +0.13 (+3.61%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Evaxion A/S stock logo

Evaxion A/S NASDAQ:EVAX

$3.24 -0.10 (-2.99%)
Closing price 04:00 PM Eastern
Extended Trading
$3.27 +0.03 (+0.99%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Radiopharm Theranostics stock logo

Radiopharm Theranostics NASDAQ:RADX

$1.52 -0.13 (-7.88%)
Closing price 04:00 PM Eastern
Extended Trading
$1.53 +0.01 (+0.66%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas